ПЕРСОНАЛИЗИРОВАННАЯ И ПРЕВЕНТИВНАЯ МЕДИЦИНА: ВОПРОСЫ РЕГУЛИРОВАНИЯ БИОБАНКОВ И ГЕНЕТИЧЕСКИХ ИССЛЕДОВАНИЙ
Письмо Министру здравоохранения РК Биртанову Е.А.
Персонализированная медицина и ее возможности в современном мире
Перспективы фармакогеномики
Полногеномный сиквенс – перспективы для медицины
Установление связей генотоп-фенотип и основа создания биобанков
Создание биобанка: организационные вопросы
Регуляторные и этические вопросы создания биобанка
Вопросы нормативно-правового регулирования персонализированной медицины и создания биобанков
Приложение: Письмо в компанию Sanofi по поводу публикации в газете «Мегаполис»
Список литературы
Оригинал документа

Список литературы

  1. Anderson JL, Mower CP, Horne BD, et al. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel (abstr). J Am Coll Cardiol 2009;53 Suppl A:A27.
  2. Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009;73:1–14.
  3. Bouman, H.J. Schömig E, van Werkum JW б et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Med. 17, 110–116 (2011).
  4. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309–17.
  5. Collet JP, Hulot JS, Pena A. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309–17.
  6. Food and Drug Administration. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug [safety announcement]. March 12, 2010. Available at: http://www.fda.gov.
  7. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806–11.
  8. Goswami S, Cheng-Lai A, Nawarskas J. Clopidogrel and genetic testing: is it necessary for everyone? Cardiol Rev.2012 Mar-Apr;20(2):96-100.
  9. Hulot J. S., Collet JP, Silvain J , et al. Cardiovascular Risk in Clopidogrel-Treated Patients to Cytochrome P450 2CP19*2 Loss-of-Function Allele or Proton Pump Inhibitor Co-administration: A Systematic Meta-Analysis,” Journal of American College of Cardiology 56 (2010): 134–43
  10. Hulot J-S. et al., Cytochrome P450 2C19 Loss-of-Function Polymorphism Is a Major Determinant of Clopidogrel Responsiveness in Healthy Subject. Blood 108, no. 7 (2006): 2244–47.
  11. Jang JS, Cho KI, Jin HY, Seo JS, Yang TH, Kim DK, Kim DS, Seol SH, Kim DI, Kim BH, Park YH, Je HG, Jeong YH, Lee SW. Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel. Am J Cardiol.2012 Aug 15;110(4):502-8.
  12. Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv.2011 Dec 1;4(6):585-94.
  13. Jin B, Ni HC, Shen W, Li J, Shi HM, Li Y. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep.2011 Mar;38(3):1697-702.
  14. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009;360:354–62.
  15. MegaJL, Simon T, Collet JP, Anderson JL, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patientstreated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010 Oct 27;304(16):1821-30.
  16. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009;302:849–57.
  17. Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512–8.
  18. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916–22.
  19. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363–75.
  20. Trenk D, Hochholzer W, Fromm MF, et al. Cytochrome P450 2C19 681G?A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51:1925–34.
  21. Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. 2012 Jul 3
  22. Zabalza M, Subirana I, Sala J, Lluis-Ganella C, Lucas G, Tomás M, Masiá R, Marrugat J, Brugada R, Elosua R. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. H2012 Jan;98(2):100-8.
Алмаз Шарман, Президент Академии профилактической медицины
Казахстан, 050008, г. Алматы, ул. Клочкова 66, офис 601
+7 (727) 317-8855
academypm@outlook.com